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The identification of the protein targets for dengue virus-specific T lymphocytes may be useful for planning
the development of subunit vaccines against dengue. We studied the recognition by murine dengue
virus-specific major histocompatibility complex class I-restricted, CD8+ cytotoxic T lymphocytes (CTL) of
dengue virus proteins using recombinant vaccinia viruses containing segments of the dengue virus genome.
CTL from H-2 mice recognized a single serotype-cross-reactive epitope on the nonstructural (NS) protein NS3.
CTL from H-? mice recognized a serotype-cross-reactive epitope that was localized to NS4a or NS4b. CTL
from H-2d mice recognized at least three epitopes: a serotype-specific epitope on one of the structural proteins,
a serotype-cross-reactive epitope on NS3, and a serotype-cross-reactive epitope on NS1 or NS2a. Our findings
demonstrate the limited recognition of dengue virus proteins by CTL from three inbred mouse strains and the
predominance ofCTL epitopes on dengue virus nonstructural proteins, particularly NS3. Since human dengue
virus-specific CTL show similar patterns of recognition, these findings suggest that nonstructural proteins
should be considered in designing vaccines against dengue.
Infections by the four serotypes of dengue virus cause
significant morbidity in tropical areas (2). This justifies
efforts to develop safe and effective vaccines against dengue.
Unfortunately, the nature of protective immunity to dengue
virus is not completely understood. Antibody responses to
one dengue virus serotype have been associated with an
increased incidence of dengue hemorrhagic fever and dengue
shock syndrome during infection with another dengue virus
serotype (6, 11, 28); therefore, a vaccine approach based on
inducing dengue virus-specific cytotoxic T lymphocytes
(CTL) might be considered. This approach has been success-
ful in protecting mice against infection with lymphocytic
choriomeningitis virus and influenza virus (14, 19). Identifi-
cation of the protein targets of dengue virus-specific T cells
should assist efforts to develop subunit vaccines against
dengue virus (2).
We previously reported initial studies of the protein tar-
gets of dengue virus-specific human and murine CD4+ T
lymphocytes (15, 26, 27). We also reported a preliminary
analysis of the protein targets of human dengue virus-
specific CD8+ CTL from a single subject (5). Other investi-
gators have detected murine dengue virus-specific CTL, but
the protein targets were not studied (10, 25). Work on other
viral systems, such as human immunodeficiency virus, dem-
onstrates that the epitopes recognized by murine and human
CTL may overlap (13). We used recombinant vaccinia
viruses containing segments of the dengue virus genome to
study the protein targets and serotype specificity of dengue
virus-specific CD8+ CTL in three inbred mouse strains. We
observed that H-2k CTL recognize a single epitope on
nonstructural (NS) protein NS3 and H-2" CTL recognize an
epitope on one of the nonstructural proteins NS4a and
NS4b. H-2d CTL recognize several epitopes: a serotype-
* Corresponding author.
cross-reactive epitope on NS3, a serotype-specific epitope
on one of the structural proteins, and at lower levels, a
serotype-cross-reactive epitope on nonstructural protein
NS1 or NS2a.
MATERIALS AND METHODS
Cells. Target cell lines were the P815 murine mastocytoma
line (H-2d), the EL4 murine lymphoma line (H-2b), and the
L929 murine fibroblast cell line (H-2k). L929 cells transfected
with the H-2Dd protein (T4.8.3 cells) (22) were graciously
provided by Carol Reiss of New York University.
Mice. Male BALB/c (H-2d), C3H (H-2?), and C57BL/6
(H-?) mice were obtained from Charles River Breeding
Laboratories (Wilmington, Mass.) and were used between 4
and 12 weeks of age.
Viruses. Mouse-adapted dengue virus type 2 (strain New
Guinea C) and dengue virus type 4 (strain 814669) were
generously provided as mouse brain homogenates by Jack
McCown, Walter Reed Army Institute of Research. Tissue
culture-adapted dengue virus type 2 (strain New Guinea
C) was kindly provided by W. Brandt, Walter Reed Army
Institute of Research, and was propagated in C6/36 cells (16).
Recombinant vaccinia viruses. The recombinant viruses
used in this study and the dengue virus genome segments
they contain are shown in Table 1. Recombinant vaccinia
viruses were constructed by insertion of dengue virus ge-
nome segments from dengue virus type 2 (strain Si) or
dengue virus type 4 (strain 814669) into the pSC11 vaccinia
virus intermediate vector (7) under control of the vaccinia
virus P7.5 early-late promoter (3, 4, 8, 9, 30).
Generation of secondary CTL. Immunization of mice and
preparation of spleen cells were ?erformed as previously
described (27). Spleen cells (3 x 10 ) were incubated in 10 ml
of RPMI 1640 supplemented with 2-mercaptoethanol (50
,uM) and 10% fetal bovine serum, with 0.5 ml of dengue virus
(approximately 5 x 106 PFU). Spleen cells from mice
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TABLE 1. Recombinant vaccinia viruses expressing dengue virus genome segments
Recognition by CTL from mouse
Virus Dengue vinru Protein sequence lineb:
orig nka H~dH-2 H-2 -2
Dengue C-pre-M-E-NS1-NS2a-NS2b-NS3-NS4a-NS4b-NS5
Recombinantsc
vvD2:C-E D2V c-pre-M-Ed - -+*
vvD2:NS1-NS2b D2V e-NS1-NS2a-NS2be - - +§
vvD4:C-NS2a D4V C-pre-M-E-NSl-NS2a - - +*
vvD4:E D4V E - -
vvD4:NS1-NS2a D4V NS1-NS2a - - +§
vvD4:NS1-NS4b D4V NS1-NS2a-NS2b-NS3-NS4a-NS4b +§ +§ +§
vvD4:NS3 D4V NS3 +§ -+§
a D2V, dengue virus type 2 strain Si; D4V, dengue virus type 4 strain 814669.
b Data are based on the results shown in Fig. 2 and 4 and Table 2. + * and +§, recognition by serotype-specific and serotype-cross-reactive CIL, respectively.
-, no recognition.
c Constructed as described in Materials and Methods.
d A shortened C protein beginning with amino acid 41 (3).
e The C-terminal 39 amino acids of E, all of NS1 and NS2a, and the N-terminal 84% of NS2b (8).
immunized with dengue virus type 2 were incubated with
dengue virus type 2, and spleen cells from mice immunized
with dengue virus type 4 were incubated with dengue virus
type 4.
Cytotoxicity assays. P815 and ELA target cells (0.5 x 106 to
1 x 106) were incubated with dengue virus or vaccinia
viruses for 2 h and then incubated overnight at 37°C. Target
cells were labelled with 250 ,Ci of Na5'CrO4 in 0.2 ml of
RPMI 1640 supplemented with 10% fetal bovine serum for 1
h and then seeded in 96-well U-bottom plates at 0.5 x 104 to
1 X 104 per well.
L929 and T4.8.3 target cells (106) were incubated with
dengue virus or vaccinia viruses for 2 h. Cells were labelled
with 250 ,Ci of Na51CrO4 simultaneously with or immedi-
ately after infection. Cells were then seeded in 96-well
flat-bottom plates at 0.5 x 104 to 1 x 104 per well and
incubated overnight at 37°C. Wells were then washed, and
fresh medium (0.1 ml per well) was added.
Secondary CTL were added to plates at various effector/
target ratios, and the plates were incubated for 4 h at 37°C.
The supernatant fluids were collected with a Titertek har-
vester, and 51Cr release was measured in a gamma counter.
Maximum 51Cr release was determined from wells contain-
ing target cells and Renex (1:40); minimum 51Cr release was
determined from wells containing target cells and medium
only. Percent specific lysis was calculated as (experimental
51Cr release - minimum 51Cr release)/(maximum 51Cr re-
lease - minimum 51Cr release) x 100.
Assays were performed in triplicate or quadruplicate
wells; the standard errors of the means of samples did not
exceed 10%. Minimum 51Cr release did not exceed 25% and
was usually less than 15% of the maximum 51Cr release.
Antibody and complement depletion of responding cells.
Anti-Thyl.2 and anti-L3T4 antibodies were obtained from
Becton Dickinson (Mountain View, Calif.). Anti-Lyt2.1 an-
tibody was obtained from Cedarlane (Hornby, Ontario,
Canada). Antibodies were used at a concentration of 1:50
(anti-Thyl.2) or 1:20. Depletions were performed as previ-
ously described (27).
Cold-target inhibition assays. Additional L929 target cells
(5 x 106) were incubated with dengue virus or vaccinia
viruses for 2 h without radioisotope and then incubated
overnight in 25-cm2 flasks at 37°C. Cells were detached with
EDTA and added to wells containing 51Cr-labelled L929 cells
to achieve the indicated ratio of unlabelled (cold) to labelled
(hot) target cells prior to the addition of effector cells.
RESULTS
Murine dengue virus-specific cytolytic activity is mediated
by MHC class I-restricted CD8+ CTL. Spleen cells from
dengue virus-immunized BALB/c, C3H, and C57BL/6 mice
incubated in vitro with dengue virus lysed dengue-infected
histocompatible target cells (see below). Depletion of effec-
tor cell populations by treatment with antibody plus comple-
ment demonstrated that the dengue virus-specific cytotoxic
cells are CD3+ CD4- CD8+ T lymphocytes (data not
shown).
To confirm that these dengue virus-specific CTL were
major histocompatibility complex (MHC) class I restricted,
we tested the activity of BALB/c CTL against T4.8.3 cells,
which express the H-21Y protein. BALB/c CTL lysed den-
gue virus type 2-infected T4.8.3 cells but not L929 cells,
which express onlyH-2k antigens (Fig. 1). This demonstrates
Target cells
0 10 20 30 40 50 60
% specific lysis
FIG. 1. Recognition of H-2-transfected L cells by dengue virus-
specific H-2d CTL. Effector cells were spleen cells from dengue
virus type 2-immunized BALB/c (H-2d) mice, cultured as described
in Materials and Methods. Target cells were dengue virus type
2-infected or uninfected P815 cells (H-2d), L929 cells (H-2k), or
T4.8.3 cells (H-2d-transfected, H-2k). The effector/target ratio was
50:1.
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FIG. 2. Recognition by H-.2 CTL of recombinant vaccinia vi-
ruses expressing dengue virus proteins. Effector cells were spleen
cells from dengue virus type 2- or type 4-immunized C3H mice,
cultured as described in Materials and Methods. Target cells were
L929 cells that were infected with dengue virus type 2 (D2V) (-),
uninfected (0), infected with wild-type vaccinia virus (i ), or
infected with recombinant vaccinia virus vvD2:C-E (S ), vvD2:
NS1-NS2b (Z ), vvD4:C-NS2a (U ), vvD4:NS1-NS4b ( ), or
vvD4:NS3 ( X ) (see Table 1). Effector/target ratio was 50:1 or 25:1
as indicated. D4V, dengue virus type 4.
that some dengue virus-specific H-2d CTL are restricted by
the H-2Dd antigen.
Dengue virus protein specificity ofH-N2 CTL. To determine
the specific virus proteins recognized by dengue virus-
specific CTL, we constructed recombinant vaccinia viruses
expressing portions of the dengue virus type 2 or dengue
virus type 4 genome. Target cells were infected with the
various recombinant vaccinia viruses and were incubated
with secondary CTL generated from dengue virus type 2- or
dengue virus type 4-immunized mice.
CTL generated from H-2k mice immunized with either
dengue virus type 2 or dengue virus type 4 showed specific
lysis of dengue virus type 2-infected L929 target cells (Fig.
2). Both populations of CTL also lysed target cells infected
with wD4:NS1-NS4b or vvD4:NS3, which expressed den-
gue virus type 4 NS1, NS2a, NS2b, NS3, NS4a, and NS4b
proteins or dengue virus type 4 NS3 protein alone, respec-
tively (Table 1 and Fig. 2). This demonstrates that H-2? CTL
recognize an epitope on the NS3 protein of dengue virus that
is cross-reactive between dengue virus type 2 and dengue
virus type 4.
To determine whether NS3 is the only protein recognized
by dengue virus-specific H-2? CTL or whether other non-
structural proteins of dengue virus coded for by vvD4:NS1-
NS4b were also recognized, we performed cold-target inhi-
bition experiments. Unlabelled L929 target cells that were
uninfected or infected with dengue virus type 2 or recombi-
nant vaccinia viruses were added to 51Cr-labelled L929
target cells at various cold/hot target cell ratios, and H-2?
effector cells were added. Unlabelled vvD4:NS3-infected
target cells inhibited the lysis of dengue virus type 2-infected
or vvD4:NS1-NS4b-infected target cells to the same degree
as the unlabelled homologous target cells (Fig. 3). This
indicates that NS3 protein is the major target for dengue
virus-specific H-2k CTL.
Dengue virus protein specificity ofH-e CTL. To determine
the dengue virus proteins recognized by H-2? CTL, we
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FIG. 3. Cold-target inhibition of recognition of dengue virus
proteins by H-? CTL. Effector cells were spleen cells from dengue
virus type 4-immunized C3H mice as in Fig. 2. Radiolabelled (hot)
target cells were L929 cells infected with dengue virus type 2 (A),
L929 cells infected with recombinant vaccinia virus wD4:NS1-
NS4b (B), or L929 cells infected with recombinant vaccinia virus
vvD4:NS3 (C). Unlabelled (cold) target cells added at the indicated
cold/hot target cell ratios were L929 cells that were infected with
dengue virus type 2 (a), uninfected (b), infected with wild-type
vaccinia virus (c), or infected with recombinant vaccinia virus
vvD4:NS1-NS4b (d) or vvD4:NS3 (e). The effector/labelled target
cell ratio was 30:1.
performed similar experiments using C57BL16 mice and EL4
target cells. CTL generated from dengue virus type 2- or
dengue virus type 4-immune mice showed specific lysis of
dengue virus type 2-infected targets and targets infected with
vvD4:NS1-NS4b, which expressed dengue virus type 4
nonstructural proteins NS1 through NS4b (Table 1 and Fig.
4). This demonstrates that H-2b CTL recognize one or more
serotype-cross-reactive epitopes on the dengue virus non-
structural proteins. H-? CTL did not lyse target cells
infected with wD2:NS1-NS2b, which expresses dengue
virus type 2 NS1, NS2a, and 84% of NS2b, or vvD4:NS3,
(c 60-
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Effectors
FIG. 4. Recognition by H-2b CTL of recombinant vaccinia vi-
ruses expressing dengue virus proteins. Effector cells were spleen
cells from dengue virus type 2- or dengue virus type 4-immunized
C57BV6 mice, cultured as described in Materials and Methods.
Target cells were EIA cells that were infected with dengue virus
type 2 (D2V) (U), uninfected (0), infected with wild-type vaccinia
virus ( I ), or infected with recombinant vaccinia virus vvD2:C-E(L6 ), vvD2:NS1-NS2b ( a ), vvD4:C-NS2a ( ), wD4:NS1-NS4b
(s)& vvD4:NS1-NS2a ( [), or vvD4:NS3 (5) (see Table 1).
Effector/target ratio was 50:1 or 25:1 as indicated. D4V, dengue
virus type 4.
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TABLE 2. Protein specificity of dengue virus-specific
BALB/c CTL'
% Specific lysis for the following
effector cells and effector/target ratioc:
P815 target cells' D2V D4V
50:1 25:1 50:1 25:1
Expt 1
D2V-infected 2 65 85
Uninfected 36 23 37 29
Vaccinia virus control 30 18 30 20
vvD2:C-E 49 3X 38 27
wD2:NS1-NS2b 41 26 49 37
wD4:C-NS2a 38 20 69 u
vvD4:E 38 22 33 23
wD4:NS1-NS2a 37 20 52 41
wD4:NS1-NS4b 5 34 60 5
Expt 2
D2V-infected ND ND 66 40
Uninfected ND ND 28 15
Vaccinia virus control ND ND 27 17
wD4:C-NS2a ND ND 43 22
vvD4:E ND ND 23 12
vvD4:NS3 ND ND 45 X
a D2V and D4V, dengue virus type 2 and type 4, respectively.
b P815 target cells were uninfected or infected with dengue virus type 2 or
wild-type or recombinant vaccinia viruses.
c Spleen cells from mice immunized with dengue virus type 2 or 4 were
cultured as described in Materials and Methods. Also, see Materials and
Methods for the method of calculation of percent specific lysis. Values that
are >3 standard deviations higher than the corresponding values for unin-
fected target cells and target cells infected with wild-type vaccinia virus are
underlined. ND, not determined.
which expresses dengue virus type 4 NS3 protein (Fig. 4),
demonstrating that the serotype-cross-reactive epitope(s)
lies on the dengue virus nonstructural protein NS4a or NS4b
or the C-terminal 16% of NS2b.
Dengue virus protein specificity of H-2d CTL. We also
determined the dengue virus protein specificity ofH-2d CTL,
using BALB/c mice and P815 target cells. As was observed
with H-2k and H-2b CTL, CTL generated from dengue virus
type 2- or dengue virus type 4-immunized H-2d mice showed
specific lysis of dengue virus type 2-infected target cells
(Table 2), demonstrating a serotype-cross-reactive CTL re-
sponse. Both populations of CTL also lysed target cells
infected with vvD4:NS1-NS4b. As was seen with H-2k CTL,
H-2d CTL did recognize target cells infected with vvD4:NS3
(Table 2 [experiment 2]), demonstrating that H-2d CTL
recognize an epitope on the NS3 protein.
In addition, there were important differences in specificity
between the dengue virus type 2- and dengue virus type
4-immune H-2d CTL populations. CTL from dengue virus
type 2-immunized H-2d mice lysed target cells infected with
wD2:C-E but not target cells infected with vvD4:C-NS2a,
whereas the reverse was true of CTL from dengue virus type
4-immunized H-2d mice (Table 2). This indicates that H-2
CTL recognize a serotype-specific epitope on one of the
dengue virus structural proteins. The failure of dengue virus
type 4-specific H-2d CTL to recognize target cells infected
with wD4:E (Table 2) suggests that one of the other struc-
tural proteins, C or pre-M, contains a CTL epitope.
CTL from dengue virus type 4-immunized H-2d mice but
not CTL from dengue virus type 2-immunized H-2d mice
showed lower but still significant levels of lysis of target cells
infected with vvD4:NS1-NS2a and wD2:NS1-NS2b (Table
2). This suggests that H-2" CTL recognize another serotype-
cross-reactive epitope on dengue virus protein NS1 or NS2a.
Lysis of target cells infected with vvD4:C-NS2a was always
significantly higher than lysis of target cells infected with
vvD4:NS1-NS2a, suggesting that there are CTL epitopes on
several dengue virus proteins. These results are summarized
in Table 1 and show that H-2d CTL recognize several dengue
virus epitopes, both serotype specific and serotype cross-
reactive.
DISCUSSION
Murine dengue virus-specific MHC class I-restricted,
CD8+ CTL have not been well characterized (10, 25). We
have analyzed the serotype specificity and protein specificity
of these CTL using recombinant vaccinia viruses expressing
dengue virus type 2 or dengue virus type 4 proteins. Our
results show that dengue virus-specific H-2k CTL exclu-
sively recognize a dengue virus type 2 and dengue virus type
4 cross-reactive epitope on the nonstructural protein, NS3.
Dengue virus-specific H-2b CTL recognize a dengue virus
type 2 and dengue virus type 4 cross-reactive epitope(s) on a
different nonstructural protein, probably NS4a or NS4b.
Further studies using additional recombinants which express
isolated dengue virus proteins will be necessary to identify
which of these proteins contains the epitope(s) recognized
by H-2b CTL.
Dengue virus-specific H-2d CTL recognized at least three
dengue virus epitopes. Like H-2/ CTL, these CTL recog-
nized a dengue virus type 2 and dengue virus type 4
cross-reactive epitope on NS3. In addition, H-2d CTL rec-
ognize a serotype-specific CTL epitope on one of the struc-
tural proteins of dengue virus, probably C or pre-M. CTL
from dengue virus type 4-immune H-2d mice also recognized
a dengue virus type 2 and dengue virus type 4 cross-reactive
epitope on the NS1 or NS2a protein, although at levels lower
than the levels of recognition of the other CTL epitopes. We
attribute the failure of CTL from dengue virus type 2-immu-
nized H-2d mice to lyse target cells expressing NS1 and
NS2a proteins to a less efficient stimulation of NS1- and
NS2a-specific CTL in that culture.
We found that CD8+ CTL from each mouse strain recog-
nized a very limited number of dengue virus epitopes, as few
as one to three CTL epitopes on the entire genome, which
encodes 3,386 amino acids (21, 29). Our preliminary studies
suggest that this holds for human dengue virus-specific
CD8+ CTL as well (5), although human and murine dengue
virus-specific CD4+ T cells appear to recognize a larger
number of epitopes (15, 26). Similarly, for Kunjin virus
(another flavivirus), CD8+ CTL from mice of four of the five
H-2 haplotypes studied recognized only a single immuno-
dominant epitope (12). In contrast, murine influenza virus-
specific CTL recognized three or four virus proteins in the
several mouse strains tested (1). The limited recognition of
flaviviruses by CTL suggests that flaviviruses may have
mutations in protein sequences that are efficiently presented
with MHC antigens.
We found a predominance of CTL epitopes on nonstruc-
tural proteins, as has been observed with other viruses such
as herpes simplex virus (23). In particular, the nonstructural
protein, NS3, was important for recognition by CD8+ CTL.
CTL from two of the three mouse strains tested recognized
an epitope on NS3. NS3 has been shown to be a major site
of human CD4+ and CD8+ T-cell epitopes (5, 18, 20). The
major Kunjin virus epitope for murine H-2k, H-2d, and H-2'
CD8+ CTL was also localized to a region containing the last
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34 amino acids of NS3 and the first 65 amino acids of NS4a
(12). It is not known whether the intracellular trafficking of
NS3 is different from that of other flavivirus proteins or
whether mutations of NS3 which might escape presentation
with MHC antigens are lethal for the virus. However, the
reproducibility of recognition of NS3 by T cells in humans
and mice suggests that NS3 may be worth considering for
experimental subunit vaccines against dengue.
Our findings may help to explain the protective effects of
some candidate subunit vaccines against lethal intracerebral
infection of mice with dengue virus. Several studies have
reported protection of mice after immunization with recom-
binant dengue virus proteins in the absence of detectable
antibodies to dengue virus. These preparations have in-
cluded recombinant vaccinia viruses expressing C, pre-M,
and E proteins or M protein alone (3, 4). Our study suggests
that immunization of BALB/c mice with vaccines containing
structural proteins might have induced dengue virus-specific
CTL, which could have contributed to the protective immu-
nity.
Vaccination designed to induce CTL responses has pro-
tected against lethal infection with lymphocytic choriomen-
ingitis virus (14), but it is impossible to predict whether this
approach will be beneficial or harmful in dengue virus
infection of humans. CTL induced by vaccination worsen
the clinical manifestations of lymphocytic choriomeningitis
virus infection under certain conditions (24). We recently
found evidence that dengue hemorrhagic fever and dengue
shock syndrome are associated with high levels of activation
of CD4+ and CD8+ T cells as measured by serum soluble-
CD4, soluble-CD8, and soluble-interleukin-2 receptor levels
(17). The majority of CTL responses we observed in this
study, and in our studies of the human CTL responses to
dengue virus (5, 15), were directed at serotype-cross-reac-
tive epitopes and could be activated in secondary dengue
virus infections. An immunopathological role for cross-
reactive T cells in dengue is difficult to prove in the murine
model because dengue virus infections do not cause hemor-
rhagic fever in mice.
Effective vaccines should presumably generate both ap-
propriate humoral immunity and appropriate cellular immu-
nity to provide the best balance of protective immune
responses. Further studies on the CTL responses to dengue
virus should provide additional information to guide devel-
opment of safe and effective vaccines.
ACKNOWLEDGMENTS
We thank Jurand Janus for technical assistance.
This work was supported by Public Health Service grant NIH-
T32-AI07272 and Physician Scientist award NIH-K11-AI00971 from
the National Institutes of Health.
REFERENCES
1. Bennink, J. R., J. W. Yewdell, G. L. Smith, and B. Moss. 1987.
Anti-influenza virus cytotoxic T lymphocytes recognize the
three viral polymerases and a nonstructural protein: responsive-
ness to individual viral antigens is major histocompatibility
complex controlled. J. Virol. 61:1098-1102.
2. Brandt, W. E. 1990. Development of dengue and Japanese
encephalitis vaccines. J. Infect. Dis. 162:577-583.
3. Bray, M., and C. J. Lai. 1991. Dengue virus premembrane and
membrane proteins elicit a protective immune response. Virol-
ogy 185:505-508.
4. Bray, M., B. Zhao, L. Markoff, K. H. Eckels, R. M. Chanock,
and C.-J. Lai. 1989. Mice immunized with recombinant vaccinia
virus expressing dengue 4 virus structural proteins with or
without nonstructural protein NS1 are protected against fatal
dengue virus encephalitis. J. Virol. 63:2853-2856.
5. Bukowski, J. F., I. Kurane, C.-J. Lai, M. Bray, B. Falgout, and
F. A. Ennis. 1989. Dengue virus-specific cross-reactive CD8+
human cytotoxic T lymphocytes. J. Virol. 63:5086-5091.
6. Burke, D. S., A. Nisalak, D. E. Johnson, and R. M. Scott. 1988.
A prospective study of dengue infections in Bangkok. Am. J.
Trop. Med. Hyg. 38:172-180.
7. Chakrabarti, S., K. Brechling, and B. Moss. 1985. Vaccinia virus
expression vector: coexpression of P-galactosidase provides
visual screening of recombinant virus plaques. Mol. Cell. Biol.
5:3403-3409.
8. Falgout, B., M. Bray, J. J. Schlesinger, and C. J. Lai. 1990.
Immunization of mice with recombinant vaccinia virus express-
ing authentic dengue virus nonstructural protein NS1 protects
against lethal dengue virus encephalitis. J. Virol. 64:4356-4363.
9. Falgout, B., M. Pethel, Y.-M. Zhang, and C.-J. Lai. 1991. Both
nonstructural proteins NS2B and NS3 are required for the
proteolytic processing of dengue virus nonstructural proteins. J.
Virol. 65:2467-2475.
10. Gajdosova, E., C. Oravec, and V. Mayer. 1981. Cell-mediated
immunity in flavivirus infections. I. Induction of cytotoxic T
lymphocytes in mice by an attenuated virus from the tick-borne
encephalitis complex and its group-reactive character. Acta
Virol. 25:10-18.
11. Halstead, S. B., S. Nimmannitya, and S. N. Cohen. 1970.
Observations related to pathogenesis of dengue hemorrhagic
fever. IV. Relation of disease severity to antibody response and
virus recovered. Yale J. Biol. Med. 42:311-328.
12. Hill, A. B., A. Mullbacher, C. Parrish, G. Coia, E. G. Westaway,
and R. V. Blanden. 1992. Broad cross-reactivity with marked
fine specificity in the cytotoxic T cell response to flaviviruses. J.
Gen. Virol. 73:1115-1123.
13. Hosmalin, A., M. Clerici, R. Houghten, C. D. Pendleton, C.
Flexner, D. R. Lucey, B. Moss, R. N. Germain, G. M. Shearer,
and J. A. Berzofsky. 1990. An epitope in human immunodefi-
ciency virus 1 reverse transcriptase recognized by both murine
and human cytotoxic T lymphocytes. Proc. Natl. Acad. Sci.
USA 87:2344-2348.
14. Klavinskis, L. S., J. L. Whitton, E. Joly, and M. B. A. Oldstone.
1990. Vaccination and protection from a lethal viral infection:
identification, incorporation, and use of a cytotoxic T lympho-
cyte glycoprotein epitope. Virology 178:393-400.
15. Kurane, I., M. A. Brinton, A. L. Samson, and F. A. Ennis. 1991.
Dengue virus-specific, human CD4' CD8- cytotoxic T-cell
clones: multiple patterns of virus cross-reactivity recognized by
NS3-specific T-cell clones. J. Virol. 65:1823-1828.
16. Kurane, I., D. Hebblewaite, W. E. Brandt, and F. A. Ennis.
1984. Lysis of dengue virus-infected cells by natural cell-
mediated cytotoxicity and antibody-dependent cell-mediated
cytotoxicity. J. Virol. 52:223-230.
17. Kurane, I., B. L. Innis, S. Nimmannitya, A. Nisalak, A. Meager,
J. Janus, and F. A. Ennis. 1991. Activation of T lymphocytes in
dengue virus infections. J. Clin. Invest. 88:1473-1480.
18. Kurane, I., B. L. Innis, S. Nimmannitya, A. Nisalak, A. L.
Rothman, P. G. Livingston, J. Janus, and F. A. Ennis. 1990.
Human immune responses to dengue viruses. Southeast Asian
J. Trop. Med. Public Health 21:658-662.
19. Kuwano, K., M. Scott, J. F. Young, and F. A. Ennis. 1989.
Active immunization against virus infections due to antigenic
drift by induction of crossreactive cytotoxic T lymphocytes. J.
Exp. Med. 169:1361-1371.
20. Livingston, P. G., I. Kurane, and F. A. Ennis. Unpublished data.
21. Mackow, E., Y. Makino, B. Zhao, Y. M. Zhang, L. Markoff, A.
Buckler-White, M. Guiller, R M. Chanock, and C. J. Lai. 1987.
The nucleotide sequence of dengue type 4 virus: analysis of
genes coding for non-structural proteins. Virology 159:217-228.
22. Margulies, D. H., G. A. Evans, K. Ozato, R. D. Camerini-Otero,
K. Tanaka, E. Appella, and J. G. Seidman. 1983. Expression of
H-2Dd and H-2Ld mouse major histocompatibility antigen genes
after DNA-mediated gene transfer. J. Immunol. 130:463-470.
23. Martin, S., R. J. Courtney, G. Fowler, and B. T. Rouse. 1988.
Herpes simplex virus type 1-specific cytotoxic T lymphocytes
recognize virus nonstructural proteins. J. Virol. 62:2265-2273.
VOL. 67, 1993
 at UNIV O
F M
ASS M
ED SCH on August 4, 2008 
jvi.asm.org
D
ow
nloaded from
 
806 ROTHMAN ET AL.
24. Oehen, S., H. Hengartner, and R. M. Zinkernagel. 1991. Vacci-
nation for disease. Science 251:195-198.
25. Pang, T., S. Devi, R. V. Blanden, and S. K. Lam. 1988. T
cell-mediated cytotoxicity against dengue-infected target cells.
Microbiol. Immunol. 32:511-518.
26. Rothman, A. L., I. Kurane, F. A. Ennis, C. J. Lai, Y. M. Zhang,
M. Bray, B. Falgout, B. Zhao, and J. J. Schlesinger. 1990.
Lymphocyte proliferative responses to dengue virus E and NS1
proteins in BALB/c mice, p. 135-138. In F. Brown, R. M.
Chanock, H. S. Ginsberg, and R. A. Lemer (ed.), Vaccines 90:
modern approaches to new vaccines including prevention of
AIDS. Cold Spring Harbor Laboratory, Cold Spring Harbor,
N.Y.
27. Rothman, A. L., I. Kurane, Y.-M. Zhang, C.-J. Lai, and F. A.
Ennis. 1989. Dengue virus-specific murine T-lymphocyte prolif-
eration: serotype specificity and response to recombinant viral
proteins. J. Virol. 63:2486-2491.
28. Sangdawibha, N., S. Rojanasuphot, S. Ahandrik, S. Viri-
yapongse, S. Jatanasen, V. Salitul, B. Phanthumachinda, and
S. B. Halstead. 1984. Risk factors in dengue shock syndrome: a
prospective epidemiologic study in Rayong, Thailand. Am. J.
Epidemiol. 120:653-669.
29. Zhao, B., E. Mackow, A. Buckler-White, L. Markoff, R. M.
Chanock, C. J. Lai, and Y. Makino. 1986. Cloning full-length
dengue type 4 viral DNA sequences: analysis of genes coding
for structural proteins. Virology 155:77-88.
30. Zhao, B., G. Prince, R. Horswood, K. Eckels, P. Summers, R.
Chanock, and C.-J. Lai. 1987. Expression of dengue virus
structural proteins and nonstructural protein NS1 by a recom-
binant vaccinia virus. J. Virol. 61:4019-4022.
J. VIROL.
 at UNIV O
F M
ASS M
ED SCH on August 4, 2008 
jvi.asm.org
D
ow
nloaded from
 
